

AGENDA

DAY 1			
TIMING	DURATION (min)	TOPIC	SPEAKER
8:30-9:00	30	Registration	
9:00-9:10	10	Introduction	Péter Krajcsi , PhD, Chief Scientific Officer, SOLVO Biotechnology, Hungary
9:10-9:50	40	Keynote: Transporters in Drug Development – Emerging Themes from the ITC	Maciej Zamek-Glyszczynski , PhD, Director, DMPK, GlaxoSmithKline, King of Prussia, USA
New Tools for old barriers; Chair: Péter Krajcsi, PhD, Chief Scientific Officer, SOLVO Biotechnology, Hungary			
9:50-10:20	30	Tools to study pulmonary drug permeability	Cynthia Bosquillon , PhD, Lecturer in Drug Delivery, School of Pharmacy, University of Nottingham, Nottingham, United Kingdom
10:20-10:50	30	A Review of HepatoPac® Products and Technology for DMPK and Toxicology Applications	Jack McGeehan , M.S., Vice President of Operations, Ascendance Biotechnology, Inc. (Formerly Hepregen Corporation), Medford, Massachusetts, USA
10:50-11:20	30	Coffee Break	
11:20-11:50	30	A Proximate proximal tubule cells as predictive in vitro models of nephrotoxicity	Colin Brown , PhD, Associate Professor, Institute for Cell & Molecular Biosciences, Medical School Newcastle University, Newcastle, UK
11:50-12:05	15	Characterization and regulation of the expression of drug transporters in human skin	Hanan Osman-Ponchet , PhD, Metabolism Manager, Department of Drug Metabolism and Pharmacokinetics, Galderma R&D, Sophia-Antipolis, France
12:05-12:20	15	Transport of ribavirin across the rat and human placental barrier; role of nucleoside transporters	Sára Karbanová , MSc, PhD student, Department of Pharmacology and Toxicology Faculty of Pharmacy in Hradec Kralove, Charles University in Prague, Czech Republic
12:20-13:20	60	Lunch Break	
13:20-14:00	40	Keynote: Refinement of in vitro tools for transporter assessment and IVIVE	Mohammed Ullah , PhD, Group Head, Cellular Transport (ADME), F. Hoffmann-La Roche, Basel, Switzerland
Tools for translational transporter science; Chair: Anna Klukovits, PhD, Study Manager, SOLVO Biotechnology, Hungary			
14:00-14:30	30	The Impact of BBB and BCSFB Transporters in translational CNS drug distribution models	Elizabeth CM de Lange , PhD, Associate professor, Head Target Site Equilibration Group, Leiden Academic Centre for Drug Research, Leiden University Gorlaeus Laboratories, Leiden, The Netherlands
14:30-15:00	30	Regulation of hepatic transporters in isolated hepatocytes: Issues and opportunities	Lassina Badolo , PhD, Principal Scientist, Discovery DMPK, Lundbeck AS, Copenhagen, Denmark
15:00-15:30	30	Coffee Break	
15:30-16:00	30	Humanized Animal Models - Potential Tools for the Study of Drug Transporters?	Laurent Salphati , PhD, Senior Scientist, Drug Metabolism and Pharmacokinetics, Genentech, South San Francisco, USA
16:00-16:15	15	Use of Förster resonance energy transfer (FRET) for functional characterization of OATP2B1	Paul Hagen , MSc, PhD student, University Medicine Greifswald, Greifswald, Germany
16:15-16:30	15	Protein kinase c-dependent regulation of human hepatic drug transporter expression	Abdullah Mayati , PhD., Postdoc, Institut de Recherches en Santé, Environnement et Travail (IRSET), Rennes, France
16:30-18:00	105	POSTER SESSION	
18:00-21:00	180	DINNER	
DAY 2			
TIMING	DURATION (min)	TOPIC	SPEAKER
9:00-9:40	40	Keynote: The concept of chemoimmunity in ADME-Tox studies - ABC transporters in stem cells	Balazs Sarkadi , PhD, Head of Research Group at Hungarian Academy of Sciences, Hungary
9:40-10:10	30	Coffee Break	
Transporters as Biomarkers, mediators of resistance and toxicity; Chair: Krisztina Heredi-Szabo, PhD, Head of Services, SOLVO Biotechnology, Hungary			
10:10-10:40	30	Transporters and response to drugs: beyond plasma pharmacokinetics	Andrea Calcagno , MD, DTM&H, Assistant Professor, Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy
10:40-11:10	30	Pharmacologic and physiologic role of ABC drug efflux transporters in auto-immune disease	Gerrit Jansen , PhD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, The Netherlands
11:10-11:40	30	BSEP inhibition and drug induced liver injury	Gerry Kenna , PhD, Drug Safety Consultant, Macclesfield, Cheshire, UK
11:40-11:55	15	Multidrug resistance (MDR) protein activity of T lymphocytes assessed by flow cytometry is a predictor of biological treatment response in rheumatoid arthritis	Péter Szeremy , M.S, PhD student, Scientist, MDQuest Kft., Szeged, Hungary
11:55-12:10	15	Bile salt transport profiling of hepatic transporters	Peter Krajcsi , PhD, Chief Scientific Officer, SOLVO Biotechnology, Budaörs, Hungary
12:10-13:10	60	Lunch Break	
Transporters as therapeutic targets; Chair: Joe Zolnerciks, PhD, Associate Director, SOLVO Biotechnology, USA			
13:10-13:40	30	Strategies exploiting transporters to overcome drug resistance in malaria	Sanjeev Krishna , FRCP, ScD, FMedSci, Institute for Infection and Immunity, St. George's, University of London, London, UK
13:40-14:10	30	The Role of Ntcp in the hepatic uptake of Hepatitis B and D viruses: Specific Inhibition of Ntcp as a novel therapeutic option to treat infections	Stephan Urban , PhD, Professor of University Hospital Heidelberg, Department of Infectious diseases, Molecular virology, Heidelberg, Germany
14:10-14:40	30	Imaging Uptake Transporter Activity in Cancer by Positron Emission Tomography (PET)	Stefanie D. Krämer , PhD, Adjunct Professor, ETH Zürich, Zürich, Switzerland
14:40-14:55	15	Artemeter-Lumefantrine (Coartem®) therapy up-regulates in vivo the <i>Plasmodium falciparum</i> multidrug resistance protein 1 (<i>pfmdr1</i>)	Pedro Gil , PhD, Associate Professor, Drug Resistance Unit, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
14:55-15:10	15	Closing Remarks for the Conference	Péter Krajcsi , PhD, Chief Scientific Officer, SOLVO Biotechnology, Hungary
http://www.solvobiotech.com/transporter-conference-budapest-2016			